Johnson & Johnson has exercised its option to acquire Arkuda's portfolio of lysosomal function enhancers in exchange for an upfr ...
Multi-year program advancing translational medical science research and education ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback